In Vitro Maturation (IVM) of Human Oocytes



Status:Active, not recruiting
Conditions:Women's Studies
Therapuetic Areas:Reproductive
Healthy:No
Age Range:25 - 42
Updated:4/21/2016
Start Date:January 2015

Use our guide to learn which trials are right for you!

We hypothesize that the combination of natural cycle IVF or low dose gonadotropin injection
combined with In Vitro Maturation (IVM) (Natural IVF/IVM) is a viable option for a selected
population of infertility patients who cannot tolerate exogenous gonadotropins or are at
risk of ovarian hyperstimulation syndrome.

Natural IVF/IVM may be an attractive treatment alternative to conventional controlled
ovarian hyperstimulation (COH)/IVF treatment for infertile women in particular for a select
group.

Natural IVF/IVM offers several advantages over conventional COH protocols for IVF including:

1. Elimination of the need for gonadotropin ovarian stimulation

2. Elimination of risk of developing OHSS

3. Simplification of treatment, eliminating the need for frequent blood tests and
ultrasound monitoring

4. Reduced cost of treatment

5. Avoiding potential side effects of gonadotropins, including weight gain, bloating,
breast tenderness, nausea, mood swings

6. Eliminates concerns about the potential risk of malignancy that may be associated with
multiple cycles of ovarian stimulation in a predisposed population.

This pilot study will be conducted to assess the clinical efficacy of natural IVF/IVM

Inclusion Criteria:

1. Each subject must be female.

2. Each subject must have an indication for COH and IVF or ICSI.

3. Each subject must be willing and able to provide written informed consent for the
trial.

4. Each subject must be ≤42 years of age at the time of signing informed consent.

5. Each subject must have a normal cervical smear result (no atypical or abnormal cells,
or in case of atypical squamous or glandular cells, no signs of malignancy;
corresponding to Papanicolaou [PAP] I or II) obtained within 12 months prior to
signing informed consent must be available.

Exclusion Criteria:

1. Subject with premature ovarian failure.

2. Subject with endocrine abnormalities such as hyperprolactinaemia or thyroid
dysfunction.

3. Subject with malformation or absence of uterus.

4. Subject tested positive for Human Immunodeficiency Virus (HIV) or Hepatitis B (by
local laboratory; results obtained within 1 year prior to signing ICF are considered
valid).

5. Subject with contraindication or allergy/hypersensitivity to hCG, estrogen and
progesterone.
We found this trial at
1
site
Manhasset, New York 11030
?
mi
from
Manhasset, NY
Click here to add this to my saved trials